A new method that encourages cell growth may have the potential to reduce diabetes in some people.
Experts identified the new procedure in a recent paper published in the journal Diabetes Care. Experts were looking at a method that includes increased cell growth on the surface of the patient's small intestine. These new cells then encourage the pancreas to produce more insulin again.
This may make it easier for a large number of people with type 2 diabetes who use oral medications by excluding insulin injections and also may make a recovery.
This advanced and promising treatment, called "reflattening of the mucosa in the duodenum" - involves inserting a small tube into a small balloon connected to one of the limbs through the patient's mouth. The tube is then installed at the top of the small intestine, at which point the balloon is filled with hot water. Heat from hot water kills endothelial cells on the surface of the small intestine - a method called ablation therapy, then stimulates the growth of new healthy cells and increases the patient's ability to give insulin.
No needles - A new oral medication has been approved for people with type 2 diabetes
A new drug for type 2 diabetes is now the first available in pill form.
It may help patients with a cheaper and easier option to control their illness.
Researchers say the new treatment raises the possibility of new oral forms of other drugs currently available in the form of injectiononly
A new drug for type 2 diabetes can be consumed orally instead of injections.
But the new property is looking to be more than just a comfort.
The syringe can be expensive. You're doomed to injections. You need to change sharp objects and need the most appropriate technology.
"It's a lot of psychological fatigue to need to take an injection once a day or once a week," said Dr. Louis Phillipson, professor of medicine at the University of Chicago and current president of science and medicine at the American Diabetes Association.
How the drug works
The Food and Drug Administration (FDA) has allowed a tablet called Rybelsus for adults with type 2 diabetes.
This drug is the first treatment of a glucagon-like peptide (GLP-1) and no need for injections.
This type of treatment discusses the future of a peptide similar to glucagon, which stops the liver from secreting too much sugar. It also supports the pancreas to give more insulin.
People with type 2 diabetes generally do not take this protein. In some of these circumstances, doctors prescribe GLP-1.
The U.S. Food and Drug Administration (FDA) noted that Rybelsus contains an alert about a possible high risk of developing c-cell tumors, as a side effect.
Other new drugs
Philipson said the new oral drug could lead to a way forward to develop new oral production of other drugs.
He explained that there are different types of pills available for diabetics, but nothing of this kind.
Medications are usually sabotaged by stomach acids, so it was important to inject the drug to give proteins in the body and retain them.
Philipson said that since this modern drug has a way to protect protein from stomach acids, other drugs available only by injection may be used - even after diabetes medications.
New diabetes recommendations defy old guidelines
People with type 2 diabetes should have a goal of strengthening the blood protein used to help control blood sugar.
Some people are advised to cancel or refrain from increasing their medications altogether.
Advice from the American College of Physicians (ACP) focuses on a protein called HbA1C or "A1C," an important element in supporting diabetics on adjusting their average blood sugar. Sugars or glucose are associated with hemoglobin as they move through the bloodstream.
A new look at A1C
Over the years, the American Diabetes Association (ADA) noted that all diabetics care about the hbA1C target rate of less than 7 percent.
More assertively, the American Society of Endocrinologists (AACE) recommends targeting A1C, which is less than 6.5 percent.
But the final report from an accurate source of ACP is completely contradicted by ADA and AACE. Most people with type 2 diabetes are advised to care about significantly higher A1C levels - between 7 and 8 percent.
A1C measures the amount of advanced gelycogen (AGEs) produced in the bloodstream over the last three months.
This measurement is then converted to the average blood sugar of a person at this time, known as the estimated average glucose (eAG).
ACP tips clearly work against years-long diabetes education instructions that indicate that A1C is more than 7 percent higher than the risk of diabetes complications such as retinopathy and neuropathy.
People without diabetes generally monitor A1C levels below 5.7, although healthier people measure less than 5.0 percent, indicating that the blood rate is too low to roam beyond the 70 to 130 mg/dL range.
To illustrate, the presence of A1C is more than 5.7 cases of prediabetes, and A1Cs at 6.5 or more is a diseaseFor diabetes.
Individuals' deliberate desire to allow their blood sugars to remain always high enough to measure A1C between 7 and 8 per cent shows that blood sugar levels remain between 150 and 200 mg/dL, much higher than considered healthy.
However, ACP recommends the objectives of increasing blood sugar because the points that indicate that A1Cs in this area are high help with complications and appear only in patients who have excess protein in their urine, indicating an old-fashioned kidney defect.
Rather than fear of complications, the important focus of ACP is very different and is centered around the individual needs of the infected.
"ACP recommends that doctors adjust blood sugar control targets for type 2 diabetes based on a study of the benefits and harms of pharmacotherapy, patient preference, patient overall health and life expectancy, treatment costs, and care burden
Furthermore, the ACP advises that patients who have achieved A1C targets of less than 6.5% should in fact "de-condense" their diabetes control by reducing the amount of medication sought or even canceling one of their medications altogether.
New recommendations may face a backlash
In general, the effort to reach the A1C level below 6.5%, many people are expected to eliminate the expectation that after years of tiring work, they should let their blood sugar level rise above the traditional health rate.
Gary Scheiner, CDE, MS, said of integrated diabetes recommendations: "General advice like this is of valuable value." "I think this advice in particular will not succeed in ensuring patient care."
Many people with type 2 diabetes can and should seek more firm control than they are noted. Scheiner, the inventor of the well-known diabetes regulation manual, Think Like a Pancreas, said people at low risk of low blood sugar are expected to benefit from low blood sugar but have a greater risk of amore a1C vascular complications than 7 percent.
"Also, a person's daily task is clearly related to glucose control, not just long-term health problems. Targeting higher levels of glucose reduces an individual's ability to be physically, intellectually and emotionally better."
One of the least controversial ACP points of interest is to emphasize that an infected person with an expectable age of 10 years or younger (who is 80 years of age or older) or people with chronic diseases in addition to diabetes should be interested in reducing symptoms of high blood sugar instead of focusing on A1C levels.
The only exception to more flexible guidelines?
People who monitor type 2 diabetes through diet and lifestyle modifications on their own are encouraged to continue working to achieve A1C goals of less than 7 percent.
New treatment can help diabetics calm down
How treatment works
Early in the permanent monitoring of the results, this method was successful for more than a year after the contributors of the research received treatment for the first time.
This is because the lining of the small intestine is highly responsible for insulin production.
After dismantling food in the stomach, it travels to the small intestine, where glucose from this food is absorbed into the bloodstream.
This process shows that the pancreas gives insulin. This insulin contributes to the transfer of glucose to every part of the body it needs.
Without an adequate amount of insulin, the bloodstream glucose rate rises.
This results in dangerously high blood sugar, which leads to the destruction of nerve endings and blood vessels throughout the body, including the eye, fingers and toes.
The results of this new test were similar to those of patients who had gastric bypass surgery.
Experts said there is an evolution in blood sugar rates for study contributors within a few days and weeks.
This development occurred regardless of diet or weight loss.
Baker Health line explained that most people with type 2 diabetes have different levels of insulin resistance, as well as individuals who do not complain of diabetes.
And that the bodies of those in the latter group easily give more insulin to compensate for the missing, it does not appear that a person with type 2 diabetes has the ability to do so.
"Most genes associated with type 2 diabetes are associated with insulin production, not insulin resistance," Baker said.
This helps to prove that getting rid of the lining of the small intestine is very effective in normalizing the patient's ability to maintain blood sugar.
Excitement in the field
Dr. George Grunberger, FACP, FACE, founder of the Grunberger Diabetes Institute in Michigan, told Healthline that he was encouraged by the results of this research.
"Several years ago, in Chile, a similar test was under consideration involving the introduction of a balloon in the small intestine to replace the lining of the intestine, so food never approaches the wall during digestion," Grunberger explained.
The blood sugar levels of patients are controlled by themselves, easily by removing and preventing this friction with the lining of the mucosa."
Since then, Grunberger said Everyone is trying to convince the FDA of the validity of this type of test.
"If you detect people early in the diabetes game, you can put diabetes on an exemption by renewing or stopping interaction with the lining of the small intestine, but for how long?
In his own study, Grunberger sees an 80 to 95 percent success rate in achieving diabetes relief through traditional gastric bypass or gastric muzzle methods.
Both procedures involve the cancellation or reduction of contact with a specific part of the small intestine.
These types of tests have shown their ability to develop glucose tolerance almost quickly." "This shows that it is not the result of calorie limiting or weight reduction, but just to stay away from this natural interaction with the lining of the mucosa."
However, those who enjoy long-term calm as they are better able to lose and maintain weight successfully.
"I have patients who had gastric bypass surgery and who had been consuming insulin for several years before surgery," Grunberger said. "They don't need insulin anymore, they keep HbA1c at 5.2 percent, and they come back every year just to say, "Hi. "
Grunberger also has injuries that do not change their style and return most of their weight. But until then, many of them can consume other diabetes medications instead of returning to insulin.
The real difficulty that this study and the like will have to do is to confirm not only its security but also its long-term usefulness.
If the patient's success after the appearance of the mucosa in the duodenum lasts only a few years, it is not possible for insurance companies to accept the idea of paying for it.
New drug treatment options for diabetes
When you have diabetes, your body has trouble adjusting insulin. Insulin is a substance given by the pancreas that helps your body take advantage of glucose (sugar) from the food you eat. The function of insulin is to transfer glucose from the bloodstream to the cells it consumes to secure energy. But if your body doesn't produce enough insulin or doesn't use it properly, glucose stays in the blood. A long increase in blood glucose can damage parts of the body.
There are two types of diabetes: type 1 and type 2. People with type 1 diabetes cannot make insulin themselves. People with type 2 diabetes can make insulin, but their bodies are unable to consume it properly.
The only drug approved to treat people with type 1 diabetes is insulin, it comes in a variety of types. On the other hand, people with type 2 diabetes have a larger list of medications. They may need to consume more than one type of medication to treat their illness.
New diabetes drugs
In recent years, many new diabetes drugs have been developed. These include oral medications as well as injections.
New oral medications
With the exception of Steglatro, which contains only one drug, modern oral drugs used to treat type 2 diabetes are all compound drugs. Each combines two types used alone to treat type 2 diabetes.
All these types of drugs are branded drugs that do not contain generic forms.
The use of Xigduo XR, which comes as a 24-hour oral tablet, was approved for use in 2014. Xigduo XR combines metformin and dapagliflozin. Metformin contributes to making the body's tissues more sensitive to insulin. Dapagliflozin prevents little glucose in your system as blood enters through your kidneys. It also makes your body get rid of excess glucose through urine.
Synjardy, which is taken as an oral tablet, was approved for use in 2015. It combines mitformin and amphliflosin medications. Empagliflozin works in a similar way to dapagliflozin.
These new brand-name injections are not secured as generic drugs. It is used to treat type 2 or type 1 diabetes and type 2 diabetes.
These medications include a type of insulin or GLP-1 agonist or both. Various types of injected insulin act as an alternative to insulin that your body does not produce or cannot use properly. Glucagon-like peptide 1 receptor agonists (GLP-1) contribute with the pancreas to giving more insulin when your glucose level is high. It also reduces glucose absorption during digestion.
Tresiba, which was approved in 2015, is a brand-name type for the drug deglodic insulin. It is used to treat type 1 and type 2 diabetes.
Tresiba is a long-acting insulin that lasts up to 42 hours. This is longer than the popularly used insulin. It is injected only once a day.
Basaglar and Toujeo
Basaglar and Toujeo are two new types of glargine insulin. They are used to treat type 1 and type 2 diabetes and are injected only once a day.
Basaglar is a long-acting insulin therapy that was approved in 2015. AndIt is similar to another insulin drug glargine called Lantus. Toujeo is a more concentrated pattern of glargine insulin. Its use was approved in 2015.